Publications

Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.

Treating physicians use this application form to apply for a patient to access LSDP medication for hereditary tyrosinaemia (type 1) for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for Pompe disease for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS I for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS II for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS IVA for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS VI for the first time, or after a break.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Batten disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Pompe disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS I.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS II.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS IVA.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS VI.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D).

Treating Physicians use this application form to apply for a patient to access LSDP medication for Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D) for the first time, or after a break.

Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access certain medications for infantile onset lysosomal acid lipase deficiency (LAL-D) under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access asfotase alfa (Strensiq®) for perinatal- and infantile-onset hypophosphatasia under the Life Saving Drugs Program.

Treating physicians use this application form to apply for a patient to access LSDP medication for HPP for the first time, or after a break.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for HPP.

Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.

This poster outlines the COVID-19 vaccine doses recommended for each age and population group.

This manual will help Aged care providers submit a specialisation application and to learn how the Specialisation Verification assessment process works.

This fact sheet provides advice to health professionals on the changes to Meningococcal ACWY vaccines under the National Immunisation Program (NIP).

This weekly report provides a snapshot of data on the impact of COVID-19 in residential aged care facilities nationally. The report includes data on the number of services impacted and number of staff and resident cases, as well as workforce, testing and PPE provided to affected services.